Table 2. Response (%) in 38 evaluable*... | American Society of Hematology

Table 2.

Response (%) in 38 evaluable* B-CLL patients treated with subcutaneous alemtuzumab as first-line treatment

Group	OR	CR	PR	SD	PD
All patients, N = 38	87	19	68	8	5
Rai stage I or II, n = 11	100	9	91	0	0
Rai stage III or IV, n = 27	81	22	59	11	8
Age older than 65 y, n = 20	90	20	70	5	5
Age 65 years or younger, n = 18	83	17	66	11	6
Any lymph node greater than 5 cm in diameter, n = 7	86	0	86	14	0
All lymph nodes 5 cm or less in diameter, n = 24	88	21^†	67	4	8
No lymphadenopathy, n = 7	86	29	57	14	0

Group	OR	CR	PR	SD	PD
All patients, N = 38	87	19	68	8	5
Rai stage I or II, n = 11	100	9	91	0	0
Rai stage III or IV, n = 27	81	22	59	11	8
Age older than 65 y, n = 20	90	20	70	5	5
Age 65 years or younger, n = 18	83	17	66	11	6
Any lymph node greater than 5 cm in diameter, n = 7	86	0	86	14	0
All lymph nodes 5 cm or less in diameter, n = 24	88	21^†	67	4	8
No lymphadenopathy, n = 7	86	29	57	14	0

SD indicates stable disease.

Three patients who received only 1 week of treatment were excluded from the efficacy analysis.

All CRs in this category were obtained in patients with lymph nodes < 2 cm in diameter.